500257 and LUPIN Related Headlines
Go Back- Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection
- Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
- Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets
- Lupin presents phase 1 data for cancer drug LNP8701 at ASCO meeting
- Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026
- Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
- Lupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution
- Lupin receives FDA approval for famotidine injection
- Lupin Receives U.S. FDA Approval for Famotidine Injection, USP
- Lupin receives FDA approval for generic glycerol phenylbutyrate oral liquid
- Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid
- Lupin Launches Dapagliflozin Tablets in the United States
- Lupin Announces Approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
- Lupin Announces the Approval of Dapagliflozin Tablets in the United States
- Lupin completes acquisition of European eye care company VISUfarma
- Lupin Completes Acquisition of VISUfarma
- Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
- Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
- Vinita Gupta, Lupin CEO, Named to the 2026 CNBC Changemakers List of Women Transforming Business for Making Medicines Accessible and Affordable for Americans
- Lupin Announces the Approval and Launch of Brivaracetam Oral Solution in the United States
- Lupin Launches Topiramate Extended-Release Capsules in the United States
- Lupin Launches Dasatinib Tablets in the United States
- Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™
- Lupin to present phase 1 data on cancer drug at ESMO congress
- Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
- Lupin launches partnership program for long-acting injectable platform
- Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
- Lupin Announces Plans to Build a New State-of-the-Art Manufacturing Facility in Coral Springs, Florida Extending its Long-Standing Commitment to America's Patients and Healthcare Syste
- Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
- Lupin gets FDA approval for risperidone injection with exclusivity
- Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform
500257 and LUPIN Related Press Releases
Go Back- Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection
- Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
- Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets
- Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026
- Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
- Lupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution
- Lupin Receives U.S. FDA Approval for Famotidine Injection, USP
- Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid
- Lupin Launches Dapagliflozin Tablets in the United States
- Lupin Announces Approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
- Lupin Announces the Approval of Dapagliflozin Tablets in the United States
- Lupin Completes Acquisition of VISUfarma
- Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
- Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
- Vinita Gupta, Lupin CEO, Named to the 2026 CNBC Changemakers List of Women Transforming Business for Making Medicines Accessible and Affordable for Americans
- Lupin Announces the Approval and Launch of Brivaracetam Oral Solution in the United States
- Lupin Launches Topiramate Extended-Release Capsules in the United States
- Lupin Launches Dasatinib Tablets in the United States
- Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™
- Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
- Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
- Lupin Announces Plans to Build a New State-of-the-Art Manufacturing Facility in Coral Springs, Florida Extending its Long-Standing Commitment to America's Patients and Healthcare Syste
- Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
- Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform
